全球血液筛检市场

全球血液筛检市场预计2030年将达到38亿美元

全球血液筛检市场规模在2024年估计为27亿美元，预计到2030年将达到38亿美元，在分析期（2024-2030年）内复合年增长率（CAGR）为5.5%。本报告分析的细分市场之一—血液筛检试剂和试剂盒，预计将以6.3%的复合年增长率成长，并在分析期结束时达到27亿美元。血液筛检设备细分市场预计在分析期间将以3.4%的复合年增长率成长。

美国市场规模估计为7.297亿美元，而中国市场预计将以9.2%的复合年增长率成长。

据估计，2024年美国血液筛检市场规模将达7.297亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到8.477亿美元，在2024年至2030年的分析期内，复合年增长率（CAGR）将达到9.2%。其他值得关注的区域市场包括日本和加拿大，预计在分析期内，这两个市场的复合年增长率将分别达到1.7%和6.0%。在欧洲，德国的复合年增长率预计将达到约2.9%。

全球血液筛检市场—主要趋势和驱动因素摘要

为什么血液筛检对于确保医疗安全至关重要？

血液筛检是医疗保健领域的关键流程，用于在血液样本用于输血、器官移植或诊断之前，检测其中的传染性病原体、遗传性疾病和其他健康问题。这项筛检流程对于确保血液和血液製品的安全使用，以及预防爱滋病、肝炎和梅毒等疾病的传播至关重要。血液筛检在癌症和遗传性疾病等疾病的早期发现中也发挥关键作用，从而能够及时进行干预和治疗。血液筛检的准确性和可靠性至关重要，因为它们直接影响患者安全和公共卫生。随着全球对安全血液製品的需求持续增长，血液筛检已成为现代医疗保健的重要组成部分，它不仅保护患者，而且确保医疗程序的有效性。

科技进步如何改变了血液筛检流程？

技术进步彻底改变了血液筛检领域，实现了更快、更准确、更全面的检测方法。过去，筛检依赖人工方法或基础血清学检测，虽然有效，但覆盖范围有限，且需要数天才能出结果。自动化检测系统和分子诊断技术的引入显着提高了血液筛检的速度和准确性。核酸增幅检查（NAT）等技术能够更早检测出病毒和细菌病原体，从而降低输血传播感染的风险。此外，高通量筛检系统的发展使得大量血液检体的处理效率更高，这对于满足现代医疗机构的需求至关重要。因此，血液筛检技术的进步不仅提高了血液製品的安全性，也扩大了可检测疾病的范围，为预防保健奠定了基础。

血液筛检技术有哪些新兴趋势和创新？

在对更全面、快速且经济高效的诊断解决方案的需求推动下，血液筛检目前正经历重大创新。其中最显着的趋势之一是次世代定序(NGS) 在血液筛检中的广泛应用，它能够对单一血液样本中的遗传物质进行详细分析，从而识别多种病原体和遗传疾病。另一个新兴趋势是将人工智慧 (AI) 和机器学习融入血液筛检流程，透过识别传统方法可能遗漏的模式和异常情况，提高诊断准确性。此外，照护现场(POC) 设备的开发正在改变血液筛检，使其能够在包括偏远和资源匮乏地区在内的各种环境下进行快速检测，从而改善重要诊断的可及性。这些创新正在拓展血液筛检的边界，有望实现更早期的疾病发现、更个人化的治疗方案以及更佳的患者预后。

哪些因素正在推动血液筛检市场的成长？

血液筛检市场的成长受到多个关键因素的驱动，这些因素凸显了安全、准确的诊断在医疗保健领域日益增长的重要性。其中一个关键驱动因素是对血液和血液製品的需求不断增长，尤其是在医疗基础设施不断完善的新兴市场。随着手术、输血和移植数量的增加，严格血液筛检以预防感染疾病传播的需求变得愈发迫切。核酸增幅检查(NAT) 和次世代定序(NGS) 等技术的进步也透过提供更精准、更有效率的筛检方法推动了市场成长。此外，慢性病发病率的上升以及人们对早期检测和预防保健日益增长的关注，也推动了对全面血液筛检的需求。全球为提高公共卫生标准所做的努力，以及政府的各项措施和法规的支持，也进一步推动了血液筛检市场的扩张。这些因素，加上诊断技术的持续创新，凸显了血液筛检在现代医疗保健中为保障病人安全和健康所发挥的关键作用。

部分：

产品和服务（试剂和试剂盒、设备、软体和服务）、技术（核酸增幅检查(NAT)、酵素免疫分析法试验 (ELISA)、快速检测、西方墨点法、次世代定序(NGS)）、最终用途（血库、医院）

受访公司范例

• Abbott Laboratories
• Beckman Coulter, Inc.
• Becton, Dickinson &Company
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche AG
• Grifols International SA
• Ortho Clinical Diagnostics, Inc.
• Siemens Healthineers
• Thermo Fisher Scientific, Inc.

人工智慧集成

我们正在利用检验的专家内容和人工智慧工具来变革市场和竞争情报。

Market Glass, Inc. 并没有查询LLM 或产业专用的SLM 的典型方法，而是建立了一个由世界各地领域专家精心策划的内容库，其中包括视频转录、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

在最新发布的报告中，Market Glass, Inc. 将关税对地理市场的影响纳入考量，并根据公司总部所在国、製造地以及进出口（成品和OEM产品）情况，预测企业竞争格局的变化。这种复杂多变的市场现实将对竞争对手产生多方面的影响，包括销货成本增加、盈利下降和供应链重组，同时也会影响微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章 市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲
• 亚太地区
• 澳洲
• 印度
• 韩国
• 亚太其他地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 竞赛

Global Blood Screening Market to Reach US$3.8 Billion by 2030

The global market for Blood Screening estimated at US$2.7 Billion in the year 2024, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Blood Screening Reagents & Kits, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Blood Screening Instruments segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$729.7 Million While China is Forecast to Grow at 9.2% CAGR

The Blood Screening market in the U.S. is estimated at US$729.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$847.7 Million by the year 2030 trailing a CAGR of 9.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Blood Screening Market - Key Trends and Drivers Summarized

Why Is Blood Screening Essential in Ensuring Safe Healthcare Practices?

Blood screening is a critical process in healthcare, designed to detect infectious agents, genetic disorders, and other health conditions in blood samples before they are used for transfusions, organ transplants, or diagnostic purposes. This screening process is vital to ensuring that blood and blood products are safe for use, thereby preventing the transmission of diseases such as HIV, hepatitis, and syphilis. Blood screening also plays a crucial role in the early detection of conditions like cancer and inherited genetic disorders, allowing for timely intervention and treatment. The accuracy and reliability of blood screening tests are paramount, as they directly impact patient safety and public health. As the demand for safe blood products continues to rise globally, blood screening has become an indispensable component of modern healthcare, protecting patients and ensuring the efficacy of medical treatments.

How Has the Evolution of Technology Transformed Blood Screening Processes?

The field of blood screening has been revolutionized by advancements in technology, leading to faster, more accurate, and comprehensive testing methods. Traditionally, blood screening relied on manual techniques and basic serological tests, which, while effective, were limited in scope and could take days to yield results. The introduction of automated testing systems and molecular diagnostics has drastically improved the speed and accuracy of blood screening. Techniques such as nucleic acid testing (NAT) allow for the detection of viral and bacterial pathogens at a much earlier stage, reducing the risk of transmitting infections through blood transfusions. Additionally, the development of high-throughput screening systems has enabled the processing of large volumes of blood samples more efficiently, which is crucial in meeting the demands of modern healthcare facilities. As a result, the evolution of blood screening technology has not only enhanced the safety of blood products but has also expanded the range of detectable conditions, making it a cornerstone of preventive healthcare.

What Are the Emerging Trends and Innovations in Blood Screening Technology?

Blood screening is currently undergoing significant innovation, driven by the need for more comprehensive, faster, and cost-effective diagnostic solutions. One of the most notable trends is the growing use of next-generation sequencing (NGS) in blood screening, which allows for the detailed analysis of genetic material and the identification of a wide range of pathogens and genetic disorders from a single blood sample. Another emerging trend is the integration of artificial intelligence (AI) and machine learning into blood screening processes, which enhances the accuracy of diagnostics by identifying patterns and anomalies that might be missed by conventional methods. Furthermore, the development of point-of-care (POC) testing devices is transforming blood screening by enabling rapid testing in various settings, including remote and resource-limited areas, thus improving access to critical diagnostics. These innovations are pushing the boundaries of what is possible in blood screening, offering the potential for earlier detection, more personalized treatment options, and improved patient outcomes.

What Are the Factors Fueling Expansion of the Blood Screening Market?

The growth in the blood screening market is driven by several critical factors that underscore the increasing importance of safe and accurate diagnostics in healthcare. One of the primary drivers is the rising demand for blood and blood products, particularly in emerging markets where healthcare infrastructure is expanding. As more surgeries, transfusions, and transplants are performed, the need for rigorous blood screening to prevent the transmission of infectious diseases is becoming more urgent. Technological advancements, such as the adoption of nucleic acid testing (NAT) and next-generation sequencing (NGS), are also fueling market growth by offering more precise and efficient screening options. Additionally, the increasing prevalence of chronic diseases and the growing focus on early detection and preventive care are boosting the demand for comprehensive blood screening tests. The global push for improved public health standards, supported by government initiatives and regulations, is further driving the expansion of the blood screening market. These factors, combined with ongoing innovations in diagnostic technology, highlight the critical role of blood screening in modern healthcare, ensuring the safety and well-being of patients worldwide.

SCOPE OF STUDY:

The report analyzes the Blood Screening market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product & Service (Reagents & Kits, Instruments, Software & Services); Technology (Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay, Next-Generation Sequencing (NGS)); End-Use (Blood Banks, Hospitals)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 12 Featured) -

• Abbott Laboratories
• Beckman Coulter, Inc.
• Becton, Dickinson & Company
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche AG
• Grifols International SA
• Ortho Clinical Diagnostics, Inc.
• Siemens Healthineers
• Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
  • Global Economic Update
  • Blood Screening - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Safe Blood Donations Throws the Spotlight on Advanced Blood Screening Technologies
  • Increasing Incidence of Bloodborne Diseases Drives Demand for Comprehensive Blood Screening Tests
  • Advancements in Molecular Diagnostics Propel Growth in Rapid and Accurate Blood Screening Solutions
  • Shift Toward Early Disease Detection Expands Addressable Market Opportunity for Blood Screening Innovations
  • Innovations in High-Throughput Screening Accelerate Demand for Efficient Blood Testing Systems
  • Expansion of Point-of-Care Diagnostics Spurs Growth in Portable and Rapid Blood Screening Devices
  • Integration of AI in Diagnostics Drives Adoption of Automated Blood Screening Systems
  • Innovations in Sample Collection and Processing Are Enhancing Blood Screening Accuracy
  • Growing Importance of Infection Control Expands Market Penetration for Comprehensive Blood Screening Solutions
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Nucleic Acid Test (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Nucleic Acid Test (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 3: World 15-Year Perspective for Nucleic Acid Test (NAT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 6: World 15-Year Perspective for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Rapid Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Rapid Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 9: World 15-Year Perspective for Rapid Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Western Blot Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Western Blot Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 12: World 15-Year Perspective for Western Blot Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Next-Generation Sequencing (NGS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Next-Generation Sequencing (NGS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 15: World 15-Year Perspective for Next-Generation Sequencing (NGS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 18: World 15-Year Perspective for Reagents & Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 21: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 24: World 15-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 25: World Recent Past, Current & Future Analysis for Blood Banks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 26: World Historic Review for Blood Banks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 27: World 15-Year Perspective for Blood Banks by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 29: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 30: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 31: World Blood Screening Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Blood Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• JAPAN
  • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• CHINA
  • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• EUROPE
  • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Blood Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
• FRANCE
  • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• GERMANY
  • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Blood Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
• AUSTRALIA
  • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• INDIA
  • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Blood Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Blood Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030
• AFRICA
  • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2015, 2025 & 2030

IV. COMPETITION